Investors
-
October 9, 2025Notice to attend the Extraordinary General Meeting in Umecrine Cognition AB, at 2:30 p.m.STOCKHOLM – October 9, 2025 The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend an extraordinary...
-
September 25, 2025Notice to attend the Extraordinary General Meeting in Umecrine Cognition ABSTOCKHOLM – September 25, 2025 The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend an extraordinary...
-
September 4, 2025Umecrine Cognition publishes data showing sustained reversal of neuroinflammation in Parkinson’s disease modelSTOCKHOLM – September 4, 2025. Umecrine Cognition today announced that the company has published results in the scientific journal Frontiers in...
Latest Annual Report
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.